Action framework
Preventing and managing the emergence of HIV drug resistance is a key component of a comprehensive and effective HIV response. This should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIV drug resistance are implemented at the clinical, programme and policy levels to address the many drivers of HIV drug resistance.
The Integrated Drug Resistance Action Framework for HIV, Hepatitis B and C, and Sexually Transmitted Infections (2026 to 2030) provides an updated, unified approach to preventing and responding to drug resistance across these diseases. Aligned with WHO strategies and grounded in equity and a people-centred, public health approach, it promotes antimicrobial stewardship and coordinated action across 5 domains: prevention and response, surveillance, research and innovation, laboratory capacity, and governance. The framework supports countries in strengthening health systems, expanding access to high-quality services, and preserving the effectiveness of lifesaving medicines.
Integrated drug resistance action framework for HIV, hepatitis B and C and sexually...
The Global Action Plan on HIV drug resistance 2017–2021 provided a comprehensive framework for global and country action and outlined a package of...
Preventing and managing the emergence of HIVDR is a key component of a comprehensive and effective HIV response, and should be integrated into broader...
Strategy
To minimize the emergence and spread of HIV drug resistance, WHO recommends that antiretroviral therapy and pre-exposure prophylaxis programmes be accompanied by the monitoring and surveillance of HIV drug resistance.
In 2004, WHO in collaboration with the HIV Drug Resistance Network – a global organization that advises WHO on HIV drug resistance – developed a strategy for the assessment and prevention of HIV drug resistance. This strategy is regularly updated to take into account the status of the ongoing scale-up of antiretroviral therapy and pre-exposure prophylaxis programmes.
HIV drug resistance surveillance guidance
To date, levels of HIV drug resistance (HIVDR) in countries scaling up ART remain manageable; however, they are slowly increasing. For example, in East...
The document summarizes a comprehensive package of HIV drug resistance surveys that should be implemented in all countries scaling-up and maintaining populations...